Travere Therapeutics, Inc. - Special Call Transcript
Good morning. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Travere Therapeutics top line interim results from Phase III DUPLEX Study of the Sparsentan in FSGS conference call. (Operator Instructions) I would like to turn the call over to Mr. Chris Cline. Please go ahead, sir.
Great. Thank you, Lisa, and good morning, and thank you all for joining us on short notice today to talk about the top line interim results from our ongoing Phase III DUPLEX Study Sparsentan in FSGS. A copy of the press release announcing the results are available on the Investors section of our website. Today's call will be led by Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by Dr. Noah Rosenberg, our Chief Medical Officer; and Dr. Bill Rote, Senior Vice President of Research and Development, will join us for the Q&A session.
Before we begin, I'd like to remind everyone that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |